{"title":"阿勒替尼治疗伴有STRN - ALK融合的甲状腺乳头状癌。","authors":"Silvia Buriolla , Giulia Zapelloni , Claudia Cipri , Giacomo Pelizzari , Alessandro Follador , Francesco Cortiula","doi":"10.1016/j.ejca.2024.115193","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Anaplastic Lymphoma Kinase (<em>ALK</em>) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of <em>ALK</em> inhibitors in advanced DTCs.</div></div><div><h3>Methods</h3><div>We report the case of a striatin (<em>STRN</em>) - <em>ALK</em> translocated advanced thyroid carcinoma.</div><div><em>STRN – ALK</em> translocation was detected by NGS – RNA analysis.</div></div><div><h3>Results</h3><div>A 74-year-old woman received first line alectinib for the treatment of a <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations.</div><div>The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.</div></div><div><h3>Conclusion</h3><div>Here we report the first case in Europe of <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma successfully treated with alectinib.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115193"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion\",\"authors\":\"Silvia Buriolla , Giulia Zapelloni , Claudia Cipri , Giacomo Pelizzari , Alessandro Follador , Francesco Cortiula\",\"doi\":\"10.1016/j.ejca.2024.115193\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Anaplastic Lymphoma Kinase (<em>ALK</em>) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of <em>ALK</em> inhibitors in advanced DTCs.</div></div><div><h3>Methods</h3><div>We report the case of a striatin (<em>STRN</em>) - <em>ALK</em> translocated advanced thyroid carcinoma.</div><div><em>STRN – ALK</em> translocation was detected by NGS – RNA analysis.</div></div><div><h3>Results</h3><div>A 74-year-old woman received first line alectinib for the treatment of a <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations.</div><div>The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.</div></div><div><h3>Conclusion</h3><div>Here we report the first case in Europe of <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma successfully treated with alectinib.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"216 \",\"pages\":\"Article 115193\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924018008\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924018008","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion
Background
Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.
Methods
We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma.
STRN – ALK translocation was detected by NGS – RNA analysis.
Results
A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations.
The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.
Conclusion
Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.
期刊介绍：
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
